Nonalcoholic fatty liver disease

Reviews in Gastroenterological Disorders

Volumn 2, Issue 1, 2002, Pages 11-19

  Yu, Andy S ^a   Keeffe, Emmet B ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Betaine; Insulin resistance; Nonalcoholic steatohepatitis; Steatosis; Ursodeoxycholic acid

Indexed keywords

ALPHA TOCOPHEROL; BETAINE; CLOFIBRATE; FREE RADICAL; GEMFIBROZIL; LIVER PROTECTIVE AGENT; METFORMIN; URSODEOXYCHOLIC ACID;

ALCOHOL ABUSE; AUTOIMMUNE DISEASE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; EXERCISE; FATTY LIVER; GENETIC DISORDER; HUMAN; HYPERTRIGLYCERIDEMIA; INSULIN RESISTANCE; LIPID STORAGE; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER FAILURE; LIVER TRANSPLANTATION; LOW FAT DIET; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; OXIDATIVE STRESS; PATHOGENESIS; PHLEBOTOMY; PREVALENCE; REVIEW; RISK FACTOR; STEATOSIS; TOXIC HEPATITIS; UNITED STATES; VIRUS HEPATITIS;

BIOPSY, NEEDLE; DISEASE PROGRESSION; FATTY LIVER; HEPATITIS; HEPATITIS, ALCOHOLIC; HUMANS; LIVER; LIVER CIRRHOSIS;

EID: 0036251833     PISSN: 1533001X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (89)

1. Non-alcoholic fatty liver: Causes and complications
2. Nonalcoholic steatohepatitis
3. Nonalcoholic fatty liver disease: A spectrum of clinical and pathological severity
4. Metabolic and nutritional considerations in non-alcoholic fatty liver
5. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease
6. Nonalcoholic steatohepatitis: A study of 49 patients
7. The natural history of nonalcoholic steatohepatitis: A follow-up study of forty-two patients for up to 21 years
8. Non-alcoholic steatohepatitis
9. The natural history of nonalcoholic fatty liver: A follow-up study
10. Clinical features and natural history of nonalcoholic steatosis syndromes
11. Nonalcoholic fatty liver disease: The most common cause of abnormal liver enzymes in the U.S. population
12. Nonalcoholic steatohepatitis: An expanded clinical entity
13. Alcohol-like liver disease in nonalcoholics: A clinical and histologic comparison with alcohol-induced liver injury
14. Comparison between nonalcoholic steatohepatitis and alcoholic hepatitis
15. Ursodeoxycholic acid or clofibrate in the treatment of non-alcohol-induced steatohepatitis: A pilot study
16. Clinicopathological comparison with alcoholic hepatitis in ambulatory and hospitalized patients
17. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis
18. Nonalcoholic steatohepatitis
19. Fatty liver hepatitis and cirrhosis in obese patients
20. Fatty liver hepatitis (steatohepatitis) and obesity: An autopsy study with analysis of risk factors
21. Fatty liver disease in morbid obesity
22. Liver histology abnormalities in the morbidity obese
23. Association of nonalcoholic fatty liver disease with insulin resistance
24. Insulin resistance in non-alcoholic steatohepatitis
25. Nonalcoholic fatty liver disease: A feature of the metabolic syndrome
26. Nonalcoholic steatohepatitis: Association of insulin resistance and mitochondrial abnormalities
27. Cryptogenic cirrhosis: Clinical characterization and risk factors for underlying disease
28. Prevalence of obesity and diabetes in patients with cryptogenic cirrhosis: A case-control study
29. Cryptogenic cirrhosis and posttransplantation nonalcoholic fatty liver disease
30. Steatosis and nonalcoholic steatohepatitis. A comparative analysis
31. Jejunoileal bypass for morbid obesity. Late follow-up in 100 cases
32. Liver transplantation for jejunoileal bypass-associated cirrhosis: Allograft histology in the setting of an intact bypassed limb
33. Liver transplantation for decompensated cirrhosis after jejunoileal bypass: A strategy for management
34. Liver transplantation in a case of steatohepatitis and subacute hepatic failure after biliopancreatic diversion for morbid obesity
35. Steatohepatitis and fatal hepatic failure after biliopancreatic diversion
36. Etiopathogenesis of non-alcoholic steatohepatitis
37. Nonalcoholic steatohepatitis
38. Prevalence and trends in overweight and obesity in three cross sectional studies of British children, 1974-94
39. Prevalence of and risk factors for hepatic steatosis in Northern Italy
40. Non-alcoholic steatohepatitis: Another disease of affluence
41. The continuing epidemics of obesity and diabetes in the United States
42. Clinical hepatology: Profile of an urban, hospital-based practice
43. Pathological and virological findings in patients with persistent hypertransaminasaemia of unknown aetiology
44. Clinicopathologic study of alcohol-like liver disease in non-alcoholics; non-alcoholic steatohepatitis and fibrosis
45. Prospective evaluation of unexplained chronic liver transaminase abnormalities in asymptomatic and symptomatic patients
46. Steatohepatitis: A tale of two "hits"?
47. Leptin
48. Pathogenesis, diagnosis, and treatment of alcoholic liver disease
49. Non-alcoholic steatohepatitis (NASH): A disease of emerging identity and importance
50. Health-related quality of life assessment in non-alcoholic steatohepatitis
51. Ratio of serum aspartate to alanine aminotransferase in chronic hepatitis. Relationship to cirrhosis
52. Nonalcoholic steatohepatitis and hepatocellular carcinoma: Natural history?
53. Does nonalcoholic steatohepatitis progress to cryptogenic cirrhosis and hepatocellular carcinoma: A case-control study
54. Relative risk of hepatocellular carcinoma in cirrhosis due to fatty liver disease: A study based on incidental hepatocellular carcinoma in liver transplant recipients
55. Hepatocellular carcinoma, liver failure and liver mortality in obesity-related cryptogenic cirrhosis
56. Hepatocellular carcinoma arising in nonalcoholic steatohepatitis
57. Nonalcoholic steatohepatitis: A proposal for grading and staging the histological lesions
58. Nonalcoholic steatohepatitis: An evolving diagnosis
59. Nonalcoholic fatty liver disease: Predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese
60. Liver fibrosis in overweight patients
61. Automated assays of serum markers of liver fibrosis predict histological fibrosis
62. An assessment of the role of liver biopsies in asymptomatic patients with chronic liver test abnormalities
63. Increased hepatic iron concentration in nonalcoholic steatohepatitis is associated with increased fibrosis
64. Hepatic iron and nonalcoholic fatty liver disease
65. Non-alcoholic steatohepatitis and iron: Increased prevalence of mutations of the HFE gene in non-alcoholic steatohepatitis
66. Iron and fibrosis in nonalcoholic fatty liver disease
67. Non-alcoholic steatohepatitis
68. Diet & exercise: Important first steps in the therapy of NASH
69. Nonalcoholic steatohepatitis in obesity: A reversible condition
70. Steatosis and cirrhosis in an obese diabetic. Resolution of fatty liver by fasting
71. Non-alcoholic steatohepatitis: Association with obesity and insulin resistance, and influence of weight loss
72. Effect of weight reduction on hepatic abnormalities in overweight patients
73. Metformin in non-alcoholic steatohepatitis
74. Metformin reverses fatty liver disease in obese, leptin-deficient mice
75. A controlled trial of gemfibrozil in the treatment of patients with nonalcoholic steatohepatitis
76. Effect of ursodeoxycholic acid plus diet in patients with non-alcoholic steatohepatitis
77. Ursodeoxycholic acid in the treatment of non-alcoholic steatohepatitis: Results of a prospective clinical controlled trial
78. Vitamin E treatment of nonalcoholic steatohepatitis in children: A pilot study
79. The effect of betaine in reversing alcoholic steatosis
80. Betaine, a promising new agent for patients with nonalcoholic steatohepatitis: Results of a pilot study
81. Phlebotomy reduces transaminase levels in patients with non-alcoholic steatohepatitis
82. Recurrence of nonalcoholic steatohepatitis in a liver transplant recipient
83. Recurrence of nonalcoholic steatohepatitis after liver transplantation
84. Recurrent nonalcoholic steatohepatitis and cirrhosis after liver transplantation
85. Frequency of nonalcoholic steatohepatitis as a cause of advanced liver disease
86. Recurrence of nonalcoholic steatohepatitis following liver transplantation
87. Development of nonalcoholic fatty liver disease after orthotopic liver transplantation for cryptogenic cirrhosis
88. NAFLD and NASH: Important diseases before and after liver transplantation
89. Is retransplantation cost effective?